根据一份提交给美国证券交易委员会（SEC）的文件披露，制药巨头礼来公司已达成协议，将以5000万美元的现金对价收购生物技术公司Sangamo Therapeutics, Inc.的特定资产。
根据协议条款，礼来除了支付5000万美元外，还将承担与所收购资产相关的部分负债。这笔交易凸显了大型制药企业通过收购外部创新资产来丰富其研发管线的战略。对于Sangamo而言，此次资产出售有助于优化其资源配置，并为其核心业务的发展提供资金支持。
根据一份提交给美国证券交易委员会（SEC）的文件披露，制药巨头礼来公司已达成协议，将以5000万美元的现金对价收购生物技术公司Sangamo Therapeutics, Inc.的特定资产。
根据协议条款，礼来除了支付5000万美元外，还将承担与所收购资产相关的部分负债。这笔交易凸显了大型制药企业通过收购外部创新资产来丰富其研发管线的战略。对于Sangamo而言，此次资产出售有助于优化其资源配置，并为其核心业务的发展提供资金支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.